Please login to the form below

Not currently logged in
Email:
Password:

plaque psoriasis

This page shows the latest plaque psoriasis news and features for those working in and with pharma, biotech and healthcare.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

with moderate-to-severe plaque psoriasis, with the company claiming its drug was more effect in clearing the skin,   worked more quickly and seemed to be effective for longer. ... clutch of new biologic therapies elbowing for market share in the

Latest news

  • Novartis gains label boost for Cosentyx Novartis gains label boost for Cosentyx

    Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis.

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    BMS also highlighted new data with BMS’ selective TYK2 inhibitor for moderate to severe plaque psoriasis, which has moved into phase 3 and is also in mid-stage testing for ... The company said the oral drug could rival the efficacy of injectable

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    BMS already has a phase III programme called POETYK underway in patients with moderate to severe plaque psoriasis, and that includes a comparative arm against Celgene’s oral therapy Otezla (apremilast) ... which brought in $1.3bn in sales last year in

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    There was also good news for Almirall, which got the nod for its delayed interleukin-23 inhibitor Ilumetri (tildrakizumab) as a treatment for moderate to severe plaque psoriasis, although it enters

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    In phase II trials the drug had a dose-dependent impact on plaque psoriasis lesions, and it is ready to move to phase III testing. ... That may be because the sector is getting increasingly crowded, with a new crop of therapies for psoriasis and atopic

More from news
Approximately 6 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Pre-registration (US) topical high potency steroid for moderate to severe plaque psoriasis.

  • 'Nothing about us without us' 'Nothing about us without us'

    Similarly, Novartis - which issued a patient declaration committing, among other things, to inviting patient input early on in their clinical trial process - recently invited people living with plaque psoriasis to attend

  • Deal Watch March 2017 Deal Watch March 2017

    Merck KGaA has partnered its product M1095 (ALX-0761), for plaque psoriasis, to Avillion.

  • Deal Watch July 2016 Deal Watch July 2016

    The product completed Phase 3 studies in moderate to severe plaque psoriasis in May 2016 and announced that the primary endpoints had been met. ... Acquisition. 78. Sun Pharma/ Almirall. Tildrakizumab (IL-23p19 inhibitor) - psoriasis. Licence.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics